NAOV
NanoVibronix, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.90
+1.06%Year over year
Reported trailing growth
- Revenue
- -18.4%
- EBITDA
- —
- EBIT
- —
- EPS
- +17.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +14.7%
- EBITDA
- -3.9%
- EBIT
- -4.2%
- Net income
- +0.2%
- EPS
- +35.2%
- Free cash flow
- +30.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025